Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will ...
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
DISC-0974: DISC-0974+Ruxolitinib Mouse Model: Wild-type mice were randomized to receive doses of placebo, ruxolitinib, DBIO-100, or a combination of ruxolitinib and DBIO-100. Results showed: ...
Disc Medicine is also set to present initial data from its RALLY-MF Phase 2 trial of DISC-0974 at the American Society of Hematology Annual Meeting. The presentation will include preliminary results ...
InvestingPro data reveals the company holds more cash than debt, with a minimal debt-to-equity ratio of 0.05. Dr. Pablo Pergola will present the poster titled "A Phase 1b, Double-Blind, ...
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional ...
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results